A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)
This study is ongoing, but not recruiting participants.
Myriad Genetic Laboratories, Inc.
Medivation is now a wholly owned subsidiary of Pfizer Inc.
Information provided by (Responsible Party):
First received: January 9, 2014
Last updated: December 13, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|